OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Al-Sawaf on the Next Steps of the CLL14 Trial in CLL

January 4th 2021

Othman Al-Sawaf, MD, a physician with the University Hospital of Cologne in Germany, discusses the next steps of the CLL14 trial in chronic lymphocytic leukemia.

Dr. Rogers on Assessing MRD After Obinutuzumab/Ibrutinib/Venetoclax in CLL

January 4th 2021

Kerry Rogers, MD, discusses the minimal residual disease assessment component of a phase 2 trial evaluating obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia.

Dr. Grothey on the Results of the ANCHOR-CRC Trial in BRAF V600E-Mutant mCRC

January 4th 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.

Dr. Corr on the Rationale to Evaluate WNT Inhibition in Gynecologic Cancers

January 4th 2021

Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

January 4th 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Dr. Siddiqi on the Rationale to Evaluate CAR T-Cell Therapy in CLL

December 23rd 2020

Tanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Barr on the Need to Develop Novel Therapies in CLL

December 23rd 2020

Paul M. Barr, MD, discusses the need to develop novel therapies in chronic lymphocytic leukemia.

Dr. Allan on the Safety Profile of Ibrutinib in High-Risk CLL

December 23rd 2020

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

Dr. Powles on the Rationale to Evaluate ctDNA in High-Risk Muscle-Invasive Bladder Cancer

December 22nd 2020

Thomas Powles, MBBS, MRCP, MD, discusses the rationale to evaluate circulating tumor DNA in high-risk muscle-invasive bladder cancer.

Dr. Al-Sawaf on the Limitations of Continuous Therapy Administration in CLL

December 22nd 2020

Othman Al-Sawaf, MD, discusses the limitations of continuous therapy administration in chronic lymphocytic leukemia.

Dr. Pusztai on the Promise of ctDNA Assays in Breast Cancer

December 22nd 2020

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCC

December 21st 2020

Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Dr. Patel Ongoing Research Efforts in Pancreatic Cancer

December 21st 2020

Reema A. Patel, MD, discusses ongoing research efforts in pancreatic cancer.

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

December 21st 2020

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

Dr. Schweizer on the Rationale for the CARD Trial in mCRPC

December 21st 2020

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Dr. Jain on the Role of BTK Inhibitors in MCL

December 21st 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Dr. Agarwal on Remaining Challenges With Abiraterone in mCSPC

December 21st 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Shore on the FDA Approval of Relugolix in Advanced Prostate Cancer

December 18th 2020

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

Dr. Braunstein on the Expanding Armamentarium in Multiple Myeloma

December 18th 2020

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Dr. Patel on Findings From the NAPOLI-1 Trial in Pancreatic Cancer

December 18th 2020

Reema A. Patel, MD, discusses findings from the NAPOLI-1 trial in pancreatic cancer.